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Primary biliary cirrhosis (PBC) is a slowly progressive cholestatic liver disease of autoimmune etiology. The initial presentation of 
PBC is various from asymptomatic, abnormal liver biochemical tests to overt cirrhosis. The diagnosis of PBC is based on 
cholestatic biochemical liver tests, presence of antimitochondrial antibody and histologic findings of nonsuppurative destructive 
cholangitis. Although the diagnosis is straightforward, it could be underdiagnosed because of its asymptomatic presentation, or 
underrecognition of the disease. UDCA in a dose of 13-15 mg/kg is the widely approved therapy which can improve the prognosis 
of patients with PBC. However, one-third of patients does not respond to UDCA therapy and may require liver transplantation. 
Every effort to diagnose PBC in earlier stage and to develop new therapeutic drugs and clinical trials should be made. (Korean J 
Hepatol 2011;17:173-179)
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Table 1. Clinical phases of primary biliary cirrhosis
Preclinical AMA reactivity in serum and/or biliary 
epithelium
Asymptomatic Elevated biochemical liver test mainly 
in ALP, GGT
Symptomatic Systemic-fatigue, pruritus
Portal hypertension-varices, ascites, 
peripheral edema
Liver insufficiency Progressive jaundice, hepatic 
encephalopathy, liver failure
AMA, antimitochondrial antibody; ALP, alkaline phosphatase; 
GGT, gamma glutamyl transpeptidase.
INTRODUCTION
Primary biliary cirrhosis (PBC) is a slowly progressive 
cholestatic liver disease of autoimmune etiology.
1 PBC is 
characterized by presence of antimichondrial antibody (AMA), 
histologic findings of portal inflammation and immune-mediated 
destruction of the intrahepatic bile ducts. It mainly affects 
middle-aged women. PBC is most prevalent in northern Europe. 
The prevalence of PBC differs considerably in different geographic 
regions, ranging from 40 to 400 per million.
1 The prevalence of 
PBC in Japan is about from 27 to 54 per million.
2 The prevalence 
of PBC in Korea has not been investigated, but PBC is 
designated as one of rare disorders by Korean government. The 
clinical characteristics of PBC in Korea are similar with those in 
regions where PBC are prevalent.
3 The manifestations and 
prognosis are various in different patients. Diagnosis in earlier 
stage and treatment with ursodeoxycholic acid (UDCA) have 
improved the prognosis in patients with PBC over the past two 
decades. This article reviews an overview of the updated 
knowledge on the diagnosis and treatment of PBC.
NATURAL HISTORY 
PBC progresses insidiously through the clinical phases: 
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Figure 1. Suggested diagnostic algorithm for patients with 
suspected primary biliary cirrhosis. 
AMA, antimitochondrial antibody; ANA, antinuclear antibody; 
ASMA, anti-smooth muscle antibody; AST, aspartate amino-
transferase.
(Table 1).
4 The preclinical phase is characterized by AMA 
reactivity with no symptom and normal biochemical liver tests. 
Then patients develop biochemical abnormalities but remain 
asymptomatic. The median time to progression from preclinical 
to asymptomatic phase was 5.6 years (range, 1-20 years).
5 
Asymptomatic phase is followed by the development of symptoms, 
usually fatigue and pruritus, and later varices, edema, or ascites 
in most untreated patients within 2 to 4 years.
6 Liver insufficiency 
is characterized by accelerated jaundice, and the prognosis is 
poor.
7 Mean survival in patients with bilirubin level of 2.0 
mg/dL is 4 years, and that in patients with bilirubin level of 6.0 
mg/dL is 2 years.
The prognosis of patients with PBC has improved significantly 
over the past 2 decades because more patients are being diagnosed 
earlier in the disease process
8 and being treated with UDCA. 
UDCA therapy significantly delayed histologic progression,
9 
decreased the development of esophageal varices,
10 and increased 
the survival in patients with PBC.
11-13 T he survival rate of 
patients with early stage (stage 1 or 2 disease) who were treated 
with UDCA for a mean of eight years was similar to that of a 
healthy control population.
14
CLININCAL MANIFESTATIONS 
PBC is now diagnosed earlier in its clinical course owing to 
easy access to biochemical tests and widespread use of 
the specific AMA assay. More than 50% of patients are 
asymptomatic at presentation.
3,15-17  Sixty percents of patients 
were asymptomatic at diagnosis also in Korea.
3 The most 
common symptoms in PBC patients at diagnosis are fatigue and 
pruritus. Fatigue has been reported in up to 78 percents of 
patients,
18-20 and does not appear to correlate with disease 
severity, histologic stage, or duration, and may impair the quality 
of life.
20 The etiology of fatigue is unknown, but may be related 
to autonomic dysfunction.
21 Pruritus, which occurs in 20 to 70 
percent of patients, can be the most distressing symptom.
22 The 
onset of pruritus usually precedes the onset of jaundice by 
months to years. The pruritus can be local or diffuse. It is usually 
worse at night and is often exacerbated by contact with wool, 
other fabrics, or heat. Its cause is unknown, but endogenous 
opioids may have a role. Unexplained discomfort in the right 
upper quadrant occurs in approximately 10 percent of patients. 
23 
Other common findings in primary biliary cirrhosis include 
hyperlipidemia, hypothyroidism, osteopenia, and coexisting 
autoimmune diseases such as Sjögren's syndrome and 
scleroderma.
24 Portal hypertension does not usually occur until 
later in the course of the disease. Malabsorption, deficiencies of 
fat-soluble vitamins, and steatorrhea are uncommon except in 
advanced disease. Rarely, patients present with ascites, hepatic 
encephalopathy, or hemorrhage from esophageal varices.
25 The 
incidence of hepatocellular carcinoma is elevated among patients 
with long-standing advanced disease.
26 Other diseases associated 
with primary biliary cirrhosis include interstitial pneumonitis, 
celiac disease, sarcoidosis, renal tubular acidosis, hemolytic 
anemia, and autoimmune thrombocytopenia.
DIAGNOSIS
The diagnosis of PBC should be suspected in the setting of 
chronic cholestasis after exclusion of other causes. The diagnosis 
is based on the following findings; 1) biochemical evidence of 
cholestasis with elevated alkaline phophatase (ALP) activity 
and/or gamma glutamyl transpeptidase (GGT), 2) presence of 
antimitochondiral antibody (AMA), and 3) histologic evidence 
of nonsuppurative cholangitis and destruction of interlobular bile 
ducts (Fig. 1). Patients are diagnosed as probable PBC if two of 
these three features are present after exclusion of biliary 
obstruction.
27 
Liver biochemical tests
The biochemical hallmarks of PBC are elevated serum ALP 
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increased level of immunoglobulins (mainly IgM) is commonly 
observed
16 while some patients with PBC may have high 
aminotransferase activities with hypergammaglobulinemia. The 
changes in biochemical tests reflect in part the severity of 
histology
28,29 and the improvement of biochemical tests after 
UDCA administration is a strong predictor of long-term 
prognosis.
30-33 In patients without cirrhosis, the degree of ALP 
elevation is related to the severity of ductopenia and inflammation 
on liver histology. The increase in aminotransferase and IgG 
levels reflects the degree of periportal and lobular necroin-
flammation. The level of serum bilirubin reflect the severity of 
ductopenia and biliary piecemeal necrosis.
29 Hyperbilirubinemia, 
hypergammaglobulinemia, hypoalbuminemia, and thrombocy-
topenia are indicators of the development of liver cirrhosis and 
portal hypertension. As in other chronic cholestatic disease, 
serum cholesterol levels often elevated.
28,29 
Autoantibodies
AMA was described in a patient with PBC in 1965 for the first 
time,
34 and has been regarded as a hallmark of PBC. Serum 
AMA is highly specific for the diagnosis of PBC and detected in 
nearly 95% of patients with PBC, while it is detected in normal 
population in about 1%.
1 When AMA is detected in asym-
ptomatic subjects with normal biochemical tests, PBC is already 
present histologically in 40% of cases,
35 and in the remaining 
patients it is likely to develop in succeeding years.
5,16,36,37 The 
antigenic target of AMA is the E2 subunits of 2-oxo acid 
dehydrogenase complexes, in particular the pyruvate dehyd-
rogenase complex (PDC)-E2.
38 AMA titer may differ by more 
than 200-fold among patients who have PBC, but in the single 
patient it remains stable over the years, and has no prognostic 
value in PBC.
39 Therefore, presence of AMA itself rather than its 
titer is important for the diagnosis. The measurement of serum 
AMA is typically based on the immunofluorescent techniques 
(the criteria of positivity, above 1:40), however, with recognition 
of antigenic determinants, enzyme-linked immunosorbent assays 
(ELISA) or western blotting assays have been developed. 
Each assay uses different epitopes, so that interpretation of 
AMA result should be considered the different sensitivity and 
specificity of the specific assay. Moreover, 5-10% of PBC 
patients did not show AMA positivity in their sera, so that liver 
biopsy is required for the suspicious cases. However, the 
comparison of AMA-positive PBC and AMA-negative PBC did 
not show significant differences in terms of clinical features, 
treatment response or prognosis.
40 Antinuclear antibodies 
(ANA) and anti-smooth muscle antibody (ASMA) are found in 
about half of PBC patients. ANAs such as anti-gp210 and 
possibly anti-p62 are detected in some of patients with PBC 
and may be associated with aggressive disease and poor 
prognosis.
41-43
Histology
Histology of PBC is characterized by chronic, nonsuppurative 
cholangitis that affects interlobular and septal bile ducts. The 
term “florid duct lesion” is often used when focal lesions show 
intense inflammatory changes and necrosis around the small bile 
ducts. The inflammatory infiltrates are comprised of plasma 
cells, macrophages, polymorphonuclear cells (especially eosi-
nophils) and sometimes epithelioid granulomas.
1 The size of the 
specimen is important and at least 10-15 portal tracts should be 
present to adequately evaluate cholangitis and ductopenia. 
Histologic lesions are classically divided into four stages. 
Stage I is characterized by portal inflammation with or without 
florid duct lesion and the inflammation is confined to the 
portal triads. Stage II is a progression of periportal lesions to 
involvement of the hepatic parenchyma, which is termed as 
interface hepatitis. Stage III is characterized by distortion of the 
hepatic architecture with numerous fibrous septa. Stage IV is 
defined as cirrhosis with the existence of regenerative nodules.
44
The role of liver biopsy for the diagnosis of PBC is limited, 
when the biochemical liver tests and AMA results are compatible 
to PBC. However, the information on the stage of PBC and the 
exclusion of the possibility of overlap syndrome such as 
autoimmune hepatitis can be obtained from the liver biopsy 
results. For AMA-negative patients, liver biopsy is mandatory 
for the diagnosis of PBC. Therefore, balanced decision should be 
made to do or not to do liver biopsy for suspicious PBC patients 
after consideration of benefit and risk or cost related to the 
invasive procedure.
TREATMENT
Ursodeoxycholic Acid (UDCA)
UDCA, the 7-beta epimer of chenodeoxycholic acid, comprised 
2% of human bile acid and has several interrelated functions 
including direct choleretic, anti-inflammatory, and antiapoptotic 
properties.
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Table 2. Therapeutic interventions for primary biliary cirrhosis
Drug Type  Relative  effectiveness  Comments 
UDCA (13-15 mg/kg/day) Bile transport  ++++ Standard of care 
Budesonide/prednisolone Immnosupressive  + Speculated of use if AIH overlap features 
Azathioprine/mycophenolate 
mofetil
Immnosupressive  - No evidence of benefit 
Methotrexate Immnosupressive  +/- 
Cyclosporin  Immnosupressive  +  Side effect profile significant
Colchicine  Cell replication  +  Potential for further study 
Bezafibrate PPARα and ρ ligand  ++  Biochemical response 
Fenofibrate PPARα ligand  ++  Biochemical response 
INT-747 Farnesoid X receptor agonist Phase II Biochemical response in phase II studies; 
pruritus as a major side effect 
Penicillamine  Copper chelation  -  No benefit 
Tamoxifen Estrogen  blocker  +  Pilot  data 
UDCA, urosodeoxycholic acid; PPARα, peroxisome proliferator-activated receptor α.
drug approved for PBC treatment by USA FDA (Table 2).
27 It 
decreases serum levels of bilirubin, ALP, aminotransferase, 
cholesterol and IgM,
46,47 and improves liver histology.
12,46 A 
combined analysis of the three largest clinical trials shows that 
UDCA prolongs survival free of liver transplantation.
48 
The adequate dosing of UDCA is important. A dose of 13-15 
mg/kg/day was superior to either a lower dose of 5-7 mg/kg/day 
or a higher dose of 23-25 mg/kg/day in biochemical responses 
and costs.
49 A complete response occurs in about 30% of patients 
treated with PBC, which was defined by normalized biochemical 
tests and stabilized or improved liver histology.
50,51 Serum ALP 
levels at 6  months after UDCA therapy can be helpful in 
predicting response to UDCA.
30,32  The life expectancy of 
patients showing the complete response during treatment with 
UDCA was similar to that of age- and sex-matched healthy 
controls for up to 20 years.
32 However, the disease progresses in 
many patients who do not show the complete response during 
UDCA therapy, for whom additional medical treatment is 
definitely required. 
Other drugs than UDCA
Other drugs for the treatment of PBC have been studied for the 
past decade as single agents or adjuvant medications. None of 
these drugs have been found beneficial as single agents, in which 
colchicines,
52,53 methotraxate,
54 penicillamine,
55 cyclosporine,
56 
corticosteroid,
57 azathioprine,
58 mycophenolate mofetil were 
included.
59 Many of these have been used in combination with 
UDCA to see if further improvement in liver disease can be 
achieved. Budesonide had been reported to improve liver 
histology and the biochemical tests of liver function when used 
with UDCA, but it may worsen osteopenia.
60 However, studies 
were of too short treatment duration to show convincingly 
whether budesonide will improve survival or not. The additions 
of colchicines,
61 methotraxate
62 and silymarin
63 to UDCA had no 
additional benefits compared with UDCA alone. 
Bezafibrate and fenofibrate (fibric acid derivatives used to 
treat hypertriglyceridemia) improved liver biochemical tests in 
pilot studies.
64,65 The proposed mechanism of action of fibric 
acid derivatives in treatment of PBC involves the regulation of 
expression of immunomodulatory proteins and lipids,
66,67 
downregulation of cholesterol 7 alpha-hydroxylase, an enzyme 
involved in the synthesis of bile acids
68 and decrease of 
multi-drug resistance (MDR) gene through the activation of 
peroxisome proliferator-activated receptor alpha.
69 Farnesoid X 
receptor (FXR) is a bile acid-activated nuclear receptor highly 
expressed in both the liver and gastrointestinal tract. It has a 
regulatory role in bile and cholesterol metabolism, and FXR 
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therapeutic option in UDCA-refractory PBC.
70 Modification of 
UDCA (nor-UDCA) with more potent choleretic property than 
UDCA improved liver biochemistry and histology in MDR2 
knockout mouse, an animal model for slcerosing cholangitis, 
which suggests that translational studies in human are required.
71 
Tamoxifen decreased alkaline phosphatase levels in two women 
who were taking it after surgery for breast cancer.
72 Although 
atorvastatin with many antiinflammatory properties was commonly 
used for control of hypercholesterolemia in PBC, it was not 
effective for PBC itself.
73 
Liver transplantation
Transplantation is the only effective treatment for those with 
decompensated cirrhosis or liver failure.
74 The outcome of liver 
transplantation in patients with PBC is more favorable than for 
other liver diseases. The survival rates at one and five years are 
92 percent and 85 percent, respectively. About 20-25% of 
patients with PBC who undergo transplantation have recurrent 
disease over 10 years. Fortunately, recurrent PBC does not affect 
patient or graft survival.
75
CONCLUSION
The diagnosis of PBC should be suspected in subjects with 
chronic cholestasis, mainly elevation of ALP after exclusion of 
other causes of hepatobiliary disease. The diagnosis of PBC is 
largely confirmed with tests for AMA. AMA is highly specific 
for the diagnosis of PBC and positive in nearly 95% of patients. 
Liver biopsy can be used especially for further evaluation in 
subjects with negative tests for AMA and suspicious overlap 
syndrome. UDCA in a dose of 13-15 mg/kg /day is the standard 
therapy for PBC treatment, however, about 40% of the patients 
do not respond to UDCA. Therefore, further efforts to develop 
new drugs and clinical trial should be warranted.
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